Form 4: CorMedix Director Kaplan Receives Equity Grant

CorMedix Inc. Director Myron Kaplan was granted 30,453 restricted stock units, vesting in full on January 26, 2027.

Summary

• Myron Kaplan, a Director of CorMedix Inc., received 30,453 restricted stock units (RSUs) on January 26, 2026.
• Each RSU represents the right to receive one share of CorMedix Inc. common stock.
• These restricted stock units will vest in full on January 26, 2027, contingent on continued service.
• Following this transaction, Myron Kaplan directly beneficially owns 231,487 shares of CorMedix Inc. Common Stock.
• Kaplan also indirectly beneficially owns 20,000 shares through his spouse and 10,000 shares through his spouse as guardian for grandchildren, but disclaims beneficial ownership of these indirect holdings.
• A Power of Attorney was executed by Myron Kaplan on January 14, 2026, appointing Beth Zelnick Kaufman as his attorney-in-fact for SEC filings, including Forms ID, 3, 4, 5, and 144.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns management interests with shareholders. It is a neutral to slightly positive event, indicating ongoing director involvement and equity-based incentives, but not a significant operational or financial development.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, promoting long-term value creation.

Risks

• The vesting of the 30,453 restricted stock units is subject to Myron Kaplan's continued service with CorMedix Inc. until January 26, 2027, meaning the shares are not guaranteed if service ceases before that date.

Future Outlook

The restricted stock units granted to Director Myron Kaplan are expected to vest in full on January 26, 2027, provided he continues his service with CorMedix Inc. until that date.

Management Comments

• "The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose." (Regarding indirect holdings)

Industry Context

This filing represents a routine insider transaction, specifically an equity grant to a director. Such compensation practices are common across publicly traded companies, including those in the biopharmaceutical sector like CorMedix Inc., to incentivize long-term commitment and align leadership interests with shareholder value. It does not reflect broader industry trends or competitive shifts.

Comparison to Industry Standards

• Granting restricted stock units to directors is a standard component of executive and director compensation packages across various industries, including pharmaceuticals and biotechnology. This practice is consistent with corporate governance benchmarks observed at companies such as Pfizer, Johnson & Johnson, and other mid-cap biotech firms, where equity awards are used to attract, retain, and motivate key personnel.
• The specific size of the grant (30,453 RSUs) would typically be benchmarked against peer companies of similar market capitalization and industry to ensure competitive and appropriate compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant to a director further aligns their financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Director (Myron Kaplan): Receives equity compensation that vests over time, providing an incentive for continued service and performance.

Next Steps

• Vesting of the 30,453 restricted stock units on January 26, 2027, subject to continued service.

Key Dates

Keywords

CorMedix Inc., CRMD, Myron Kaplan, Restricted Stock Units, RSU, Director, Insider Transaction, Form 4, Beneficial Ownership, Equity Compensation